NBER Working Paper No. 19522
Issued in October 2013
NBER Program(s): HE IO
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show generics and ``me-too'' drugs each increased consumer welfare more than $100 million in 2010, holding insurance premiums constant. However, insurance payments in 2010 fell by nearly $1 billion due to generics and rose by over $7 billion due to me-too antiulcer drugs.
The NBER Bulletin on Aging and Health provides summaries of publications like this.
You can sign up to receive the NBER Bulletin on Aging and Health by email.
Machine-readable bibliographic record -
Document Object Identifier (DOI): 10.3386/w19522
Published: Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013. "Pharmaceutical followers," International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553. citation courtesy of
Users who downloaded this paper also downloaded these:
||w18830 Effects of Pharmaceutical Promotion: A Review and Assessment
|Lewis, Rao, and Reiley
||w19520 Measuring the Effects of Advertising: The Digital Frontier
|Clark and Mitchell
||w19511 How Does Retiree Health Insurance Influence Public Sector Employee Saving?
|Aitken, Berndt, Bosworth, Cockburn, Frank, Kleinrock, and Shapiro
||w19487 The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity
|Hackmann, Kolstad, and Kowalski
||w19149 Adverse Selection and an Individual Mandate: When Theory Meets Practice